Alnylam Pharmace. buy Shooter
Start price
08.02.24
/
50%
€157.20
Target price
08.02.25
-
Performance (%)
-10.81%
Price
15:56
€140.20
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -10.81%. This prediction currently runs until 08.02.25. The prediction end date can be changed by Shooter at any time. Shooter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 2.036% | 2.036% |
| iShares Core DAX® | 0.476% | -0.039% |
| iShares Nasdaq 100 | 1.290% | 0.504% |
| iShares Nikkei 225® | 1.300% | -2.135% |
| iShares S&P 500 | 0.829% | 0.193% |